AB001 / AKSO Biopharma - LARVOL DELTA

AKSO Announces Publication of Preclinical Data Demonstrating Engineered Soluble BCMA Decoy Receptor AB001 Effectively Inhibits Multiple Myeloma and Diffuse Large B Cell Lymphoma (Businesswire) - "AB001 is an engineered high-affinity soluble BCMA decoy receptor that traps APRIL and BAFF, critical cytokines controlling B cell development and survival; AB001 effectively inhibits the development of Multiple Myeloma and Diffuse Large B Cell Lymphoma via modulating protein translation machinery; AB001 demonstrated impressive safety profile and on-target mechanism of action in non-human primates."

Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology